SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-24-026947
Filing Date
2024-03-28
Accepted
2024-03-28 09:30:01
Documents
87
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 ANNUAL REPORT ea0202482-20f_canfite.htm   iXBRL 20-F 2105178
2 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 ea020248201ex2-1_canfite.htm EX-2.1 89110
3 CAN-FITE BIOPHARMA LTD. 2023 ISRAELI SHARE OPTION PLAN ea020248201ex4-9_canfite.htm EX-4.9 102698
4 CERTIFICATION ea020248201ex12-1_canfite.htm EX-12.1 8879
5 CERTIFICATION ea020248201ex13-1_canfite.htm EX-13.1 4036
6 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM ea020248201ex15-1_canfite.htm EX-15.1 5629
7 EXECUTIVE OFFICER CLAWBACK POLICY ea020248201ex97-1_canfite.htm EX-97.1 55640
8 GRAPHIC image_001.jpg GRAPHIC 30262
9 GRAPHIC image_002.jpg GRAPHIC 13423
10 GRAPHIC image_003.jpg GRAPHIC 19637
11 GRAPHIC image_004.jpg GRAPHIC 27860
12 GRAPHIC image_005.jpg GRAPHIC 17356
13 GRAPHIC image_006.jpg GRAPHIC 20748
14 GRAPHIC fin_001.jpg GRAPHIC 2625
  Complete submission text file 0001213900-24-026947.txt   7316312

Data Files

Seq Description Document Type Size
15 XBRL SCHEMA FILE canf-20231231.xsd EX-101.SCH 66756
16 XBRL CALCULATION FILE canf-20231231_cal.xml EX-101.CAL 33629
17 XBRL DEFINITION FILE canf-20231231_def.xml EX-101.DEF 238280
18 XBRL LABEL FILE canf-20231231_lab.xml EX-101.LAB 480408
19 XBRL PRESENTATION FILE canf-20231231_pre.xml EX-101.PRE 229722
91 EXTRACTED XBRL INSTANCE DOCUMENT ea0202482-20f_canfite_htm.xml XML 598053
Mailing Address 26 BEN GURION STREET RAMAT GAN L3 5257346
Business Address 26 BEN GURION STREET RAMAT GAN L3 5257346 972 39241114
Can-Fite BioPharma Ltd. (Filer) CIK: 0001536196 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: 20-F | Act: 34 | File No.: 001-36203 | Film No.: 24794008
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)